Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
NCT06941870 · View on ClinicalTrials.gov ↗
Study Summary
The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximately 12 months.
Conditions Studied
Interventions
- DRUG Efanesoctocog alfa
Study Locations (13)
Other
- Investigational Site Number : 3920002 — Hiroshima
- Investigational Site Number : 3920001 — Saitama
- Investigational Site Number : 3920004 — Tokyo
- Investigational Site Number : 1580003 — Kaohsiung City
- Investigational Site Number : 1580001 — Taichung
- Investigational Site Number : 1580002 — Taipei
Ontario
- Investigational Site Number : 1240003 — Hamilton
- Investigational Site Number : 1240004 — Hamilton
California
- Orthopedic Institute for Children- Site Number : 8400009 — Los Angeles
Indiana
- Innovative Hematology, Inc.- Site Number : 8400006 — Indianapolis
Iowa
- University of Iowa- Site Number : 8400004 — Iowa City
Ohio
- Ohio State University Hospital East- Site Number : 8400001 — Columbus
Kanagawa
- Investigational Site Number : 3920003 — Kawasaki
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-09-23 |
| Est. Completion | 2027-10-25 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06941870
The ClinicalTrials.gov registry entry for NCT06941870 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 275 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Factor VIII Deficiency appearing as the primary indexed condition, and to 1 intervention — of which Efanesoctocog alfa is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06941870 reports 13 study locations spanning 7 distinct geographic areas — top geographies include Other, Ontario, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06941870 about?
NCT06941870 is a clinical study titled "Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy". The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximat...
What is the current status of trial NCT06941870?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2025-09-23. Estimated completion is 2027-10-25.
What conditions does trial NCT06941870 study?
This clinical trial studies the following conditions: Factor VIII Deficiency. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06941870?
The interventions under investigation include: Efanesoctocog alfa (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06941870?
This trial is sponsored by Sanofi, which has 275 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06941870 being conducted?
This trial has 13 study locations across California, Indiana, Iowa, Ohio, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.